Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.990
Open
15.990
VWAP
15.99
Vol
1.48K
Mkt Cap
150.15M
Low
15.990
Amount
23.70K
EV/EBITDA(TTM)
--
Total Shares
9.39M
EV
53.79M
EV/OCF(TTM)
--
P/S(TTM)
--
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-2.381
+5.36%
--
--
-2.352
+4.08%
--
--
-2.390
-4.02%
Estimates Revision
The market is revising Upward the revenue expectations for Korro Bio, Inc. (KRRO) for FY2025, with the revenue forecasts being adjusted by 12.4% over the past three months. During the same period, the stock price has changed by 2.83%.
Revenue Estimates for FY2025
Revise Upward
+12.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.76%
In Past 3 Month
Stock Price
Go Up
+2.83%
In Past 3 Month
5 Analyst Rating
595.75% Upside
Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 111.25 USD with a low forecast of 80.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
595.75% Upside
Current: 15.990
Low
80.00
Averages
111.25
High
180.00
595.75% Upside
Current: 15.990
Low
80.00
Averages
111.25
High
180.00
Oppenheimer
Oppenheimer
Outperform
downgrade
$155 -> $90
2025-05-13
Reason
Oppenheimer
Oppenheimer
Price Target
$155 -> $90
2025-05-13
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Korro Bio to $90 from $155 and keeps an Outperform rating on the shares following quarterly results. The firm notes KRRO-110/AATD Phase 1/2a REWRITE SAD interim readout remains on track in the second half of 2025. While Oppenheimer's fundamental outlook on Korro remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data; accordingly, the firm increases the discount rate from 30% to 40%.
H.C. Wainwright
Mitchell Kapoor
Buy
downgrade
$115 -> $100
2025-05-08
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$115 -> $100
2025-05-08
downgrade
Buy
Reason
H.C. Wainwright analyst Mitchell Kapoor lowered the firm's price target on Korro Bio to $100 from $115 and keeps a Buy rating on the shares. The firm sees Korro "as somewhat insulated from the market turmoil that rocked genetic medicines stocks this week." While the was down as much as 26% in response to Vinay Prasad's FDA appointment, this was mostly unwarranted, as KRRO-110 will not be reviewed by Dr. Prasad's division, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$130 -> $53
2025-05-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$130 -> $53
2025-05-08
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Korro Bio to $53 from $130 and keeps a Buy rating on the shares. The company reported Q1 results and announced a 20% workforce reduction to extend its cash runway into 2027 from the second half of 2026, the analyst tells investors in a research note. The firm believes Korro's catalysts are on track but adjusted its model to reflect the "increasingly competitive" alpha-1 antitrypsin deficiency landscape.
Chardan Capital
Keay Nakae
Strong Buy
Initiates
$25
2025-04-16
Reason
Chardan Capital
Keay Nakae
Price Target
$25
2025-04-16
Initiates
Strong Buy
Reason
Chardan analyst Keay Nakae initiated coverage of Korro Bio with a Buy rating and $25 price target. Korro is an "intriguing small-cap story" that now trades at a compelling entry point, the analyst tells investors in a research note. The firm cites the potential of the company's enabling design platform for ADAR RNA base-editing therapeutics for the Buy rating.
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$115
2025-03-20
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$115
2025-03-20
Reiterates
Strong Buy
Reason
RBC Capital
Luca Issi
Buy
Maintains
$105 → $95
2025-03-19
Reason
RBC Capital
Luca Issi
Price Target
$105 → $95
2025-03-19
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes that dosing for A1AT is on track with first two cohorts of healthy volunteers dosed and no serious adverse events reported to date. While Wave Life Sciences Ltd (WVE) is ahead, Korro is the better way to play RNA editing given unconstrained economics, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the company's operating expense.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Korro Bio Inc (KRRO.O) is -1.55, compared to its 5-year average forward P/E of -3.98. For a more detailed relative valuation and DCF analysis to assess Korro Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.98
Current PE
-1.55
Overvalued PE
-2.17
Undervalued PE
-5.80
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
62.87
Current PS
145.00
Overvalued PS
230.08
Undervalued PS
-104.34
Financials
Annual
Quarterly
FY2025Q2
1.46M
Total Revenue
FY2025Q2
YoY :
+12.75%
-27.20M
Operating Profit
FY2025Q2
YoY :
+18.07%
-25.77M
Net Income after Tax
FY2025Q2
YoY :
+12.76%
-2.74
EPS - Diluted
FY2025Q2
YoY :
-5.73%
-19.38M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
-1.77K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
855.5K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1445.31% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
380.3K
Volume
Months
6-9
1
24.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
855.5K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KRRO News & Events
Events Timeline
2025-08-12 (ET)
2025-08-12
07:06:23
Korro Bio reports Q2 EPS ($2.74), consensus ($2.59)
2025-07-21 (ET)
2025-07-21
08:11:28
Korro Bio receives European Medicines Agency granted ODD for KRRO-110
2025-05-07 (ET)
2025-05-07
17:25:37
Korro Bio reports Q1 EPS ($2.49), consensus ($2.62)
Sign Up For More Events
Sign Up For More Events
News
4.0
07-24BenzingaHC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
9.0
07-21NASDAQ.COMKorro Bio Announces EMA Orphan Drug Designation For KRRO-110
4.0
05-13BenzingaChardan Capital Maintains Buy on Korro Bio, Maintains $25 Price Target
Sign Up For More News
People Also Watch
LOCO
El Pollo Loco Holdings Inc
10.380
USD
0.00%
EB
Eventbrite Inc
2.610
USD
+2.76%
QTRX
Quanterix Corp
4.890
USD
+2.73%
IHRT
iHeartMedia Inc
2.145
USD
+5.67%
JOUT
Johnson Outdoors Inc
39.350
USD
0.00%
HRTG
Heritage Insurance Holdings Inc
21.510
USD
-0.88%
ACNB
ACNB Corp
44.570
USD
0.00%
NEWT
NewtekOne Inc
11.980
USD
0.00%
KLTR
Kaltura Inc
1.610
USD
0.00%
TBRG
TruBridge Inc
19.780
USD
+1.02%
FAQ
What is Korro Bio Inc (KRRO) stock price today?
The current price of KRRO is 15.99 USD — it has increased 0 % in the last trading day.
What is Korro Bio Inc (KRRO)'s business?
What is the price predicton of KRRO Stock?
What is Korro Bio Inc (KRRO)'s revenue for the last quarter?
What is Korro Bio Inc (KRRO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Korro Bio Inc (KRRO)'s fundamentals?
How many employees does Korro Bio Inc (KRRO). have?